Research progress on cardiac allograft vasculopathy
10.3969/j.issn.1674-7445.2020.01.017
- VernacularTitle:心脏移植物血管病变研究进展
- Author:
Zhenggang ZHANG
1
;
Fang ZHENG
Author Information
1. Department of Immunology, Basic Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China
- Publication Type:Research Article
- Keywords:
Heart transplantation;
Cardiac allograft vasculopathy;
Immunological factor;
T lymphocyte;
B lymphocyte;
Interleukin;
Interferon
- From:
Organ Transplantation
2020;11(1):104-
- CountryChina
- Language:Chinese
-
Abstract:
Allogeneic heart transplantation (HTx) is the primary treatment for patients with end-stage heart failure. Nevertheless, the long-term complication of cardiac allograft vasculopathy (CAV) after HTx is the main factor affecting the long-term survival of the recipients. Up to now, there is no effective methods to prevent and treat CAV. This article reviews the pathological manifestations of CAV, immunological factors of CAV and other risk factors of CAV, aiming to provide novel ideas and understanding for CAV research.
